HOME >> MEDICINE >> NEWS
Resistance to anti-flu agents increasing worldwide

Worldwide resistance to drugs used to treat influenza has increased by 12% since the mid-nineties, concludes a report published online today (Thursday September 21, 2005) by THE LANCET.

Adamantanes have been used to treat influenza A virus infections for more than 30 years. Previous surveillance studies have identified a low incidence of resistance to amantadine and rimantadine among circulating influenza virus strains. However, it has been 10 years since the last comprehensive global study of resistance to these drugs was published.

In the largest study of adamantane resistance to date, Rick Bright (Centers for Disease Control and Prevention, Atlanta, GA, USA) and colleagues screened 7000 influenza A isolates for gene mutations known to confer drug resistance. They found that drug resistance increased from 0.4% in 1994-1995 to 12.3% in 2003-2004. They also found that 61% of resistant viruses isolated since 2003 were from people in Asia. Some Asian countries had drug resistance frequencies exceeding 70%.

Dr Bright comments: "We were alarmed to find such a dramatic increase in drug resistance in circulating human influenza viruses in recent years. Our report has broad implications for agencies and governments planning to stockpile these drugs for epidemic and pandemic strains of influenzaWith the increasing rates of resistance shown here, amantadine and rimantadine will probably no longer be effective for treatment or prophylaxis in the event of a pandemic outbreak of influenza." (Quote by e-mail; does not appear in published paper)


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
21-Sep-2005


Page: 1

Related medicine news :

1. Cranberries contain possible anti-caries/anti-plaque agents
2. New contrast agents may be on horizon for better medical imaging
3. New infectious agents pose new risks for people with bleeding disorders, Jefferson hematologist says
4. Use of gastric acid-suppressive agents linked with increased risk for diarrhea infection
5. Program may improve physicians knowledge about diseases caused by bioterrorism agents
6. Gadonanotubes greatly outperform existing MRI contrast agents
7. Possible exposure to nerve agents and brain cancer deaths in Gulf War veterans
8. Herbal medicine may alter cell response to cancer therapeutic agents
9. Penn researchers discover novel pathway for increasing good cholesterol
10. Drugs users are increasingly more cautious with needles
11. Home improvement warning -- Ladder-related injuries increasing in the US

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... “Vinaya” Rednam distinguishes herself once more by being among Houston’s first plastic surgeons ... the highest quality plastic surgery care without disrupting busy schedules and maintaining the ...
(Date:8/17/2017)... ... August 17, 2017 , ... Florida Hospital Zephyrhills showcased ... community partners. The newly renovated ER was designed with patients in mind and ... semi-private rooms to deliver patient results, improve efficiencies and reduce length of stay, ...
(Date:8/17/2017)... ... August 17, 2017 , ... With the introduction of new devices, new features, ... changes to the smartwatch market. As of June 2017, nearly nine percent of U.S. ... months prior. Additionally, according to latest WEAR Report Industry Overview and Forecast from NPD’s ...
(Date:8/17/2017)... ... 17, 2017 , ... Pot Valet is a leading provider of premium medical-grade ... the state, and soon, every state in the country, the company offers patients safe, ... dispensary altogether. , According to Pot Valet, all California patients have the ...
(Date:8/17/2017)... VA (PRWEB) , ... August 17, 2017 , ... ... for Great Employers , an international competition, were announced today. The awards recognize ... products and suppliers who help to create and drive great places to work. ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/27/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST ) ... and updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a ... sales at constant currency (organic) grew by 3.9%. ... to $0.60 in the prior-year quarter. Second-quarter 2017 adjusted ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
Breaking Medicine Technology:
Cached News: